OncoCyte Corporation with ticker code (OCX) now have 4 analysts in total covering the stock. The consensus rating is pointing to ‘Hold’. The range between the high target price and low target price is between 0.46 and 0.36 and has a mean target at $.41. Now with the previous closing price of $.25 and the analysts are correct then there would likely be a percentage uptick in value of 64.0%. The 50 day MA is $.32 and the 200 day MA is $.56. The market cap for the company is $32m. You can visit the company’s website by visiting: https://oncocyte.com
The potential market cap would be $53m based on the market consensus.
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
The company is not paying dividends at this time.
